New drug cocktails aim to tame metastatic breast cancer
NCT ID NCT02057133
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests the safety of combining the targeted drug abemaciclib with various other breast cancer treatments (like letrozole, tamoxifen, or trastuzumab) in 198 people whose breast cancer has spread. The goal is to find safe combinations that may help control the disease. Participants have either hormone receptor-positive or HER2-positive metastatic breast cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
abemaciclib (a targeted cancer drug) combined with other drugs like letrozole, anastrozole, tamoxifen, exemestane, everolimus, trastuzumab, LY3023414, fulvestrant, pertuzumab, loperamide, or ongoing endocrine therapy
What this could lead to
If successful, this could help identify safe and effective drug combinations for treating metastatic breast cancer, potentially improving disease control.
What could go wrong
This is an early-phase (Phase 1b) safety study with a small number of participants. It is not designed to prove effectiveness, and some combinations may cause side effects or not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University College of Phys & Surgeons
New York, New York, 10032, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Highlands Oncology Group - Duplicate 2
Rogers, Arkansas, 72758, United States
-
Mayo Clinic
Rochester, Minnesota, 55905-0002, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Peggy and Charles Stephenson Oklahoma Cancer Center
Nashville, Tennessee, 37203, United States
-
Providence Cancer Center Oncology Hematology Care
Portland, Oregon, 97213, United States
-
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, 78229-3307, United States
-
Tennessee Oncology PLLC
Nashville, Tennessee, 37203, United States
-
Univ of Pittsburgh Cancer Inst. (UPCI)
Pittsburgh, Pennsylvania, 15213, United States
-
University of California - San Diego
La Jolla, California, 92037-0845, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232-6307, United States